Cookies Policy
X

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

Mouse strains selected for differences in sensitivity to a benzodiazepine receptor inverse agonist: pharmacological and behavioural responses

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

This Article is currently unavailable for purchase.
Add to Favorites
You must be logged in to use this functionality

Cover image Placeholder

Two strains of mice were selected for their sensitivity (BS strain) or resistance (BR strain) to a convulsant inverse agonist of the benzodiazepine receptor, methyl β-carboline-3-carboxylate or β-CCM. Initial differences between the two strains were observed for a number of biochemical and pharmacological characteristics. The resistant strain was more anxious, less aggressive, more resistant to the convulsant actions of other convulsant compounds acting on the GABA receptor complex, and more resistant to the anxiolytic and sedative effects of benzodiazepines. Standard tests used to test antidepressant compounds showed resistant subjects had a less 'depressed' profile than animals from the sensitive strain. Resistance to seizures can be explained by binding measurements: a possible explanation for the marked decrease in Bmax observed in the resistant strain may be an adaptation of the number of benzodiazepine receptors after β-CCM administration, helping the mice develop resistance to the convulsant agent. But not all behavioural and pharmacological phenomena observed can be easily explained through binding to the benzodiazepine receptor and it is likely that other biochemical processes in the brain are involved.

10.1163/156939102321781499
/content/journals/10.1163/156939102321781499
dcterms_title,pub_keyword,dcterms_description,pub_author
10
5
Loading
Loading

Full text loading...

/content/journals/10.1163/156939102321781499
Loading

Data & Media loading...

http://brill.metastore.ingenta.com/content/journals/10.1163/156939102321781499
Loading

Article metrics loading...

/content/journals/10.1163/156939102321781499
2017-12-14

Sign-in

Can't access your account?
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation